cGMP Plasmid DNA Manufacturing Services

Cell and gene therapies have experienced exponential growth in recent years as more products advance toward clinical trials and eventual commercialization. This growth, along with the rapid emergence of the mRNA vaccine market, has created intense pressure on manufacturing plasmid DNA, the genetic foundation for these therapeutic strategies. Thermo Fisher Scientific has responded by expanding cGMP plasmid DNA manufacturing capacity and solutions so you can get to market faster.

Utilizing cGMP quality plasmid material, regardless of clinical phase of use, mitigates risk to budget and timelines by preventing changes downstream and ensures compliance with evolving regulatory guidelines. Our end-to-end solutions span early translational services all the way to storage and cold chain logistics, helping to reduce complexity and risk in your value chain. Learn how our plasmid DNA solutions can reduce timelines and increase efficiency as you advance your therapy to market.